Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study
Authors:
- S.Y. RhaSRS.Y. Rha
- L.S. WyrwiczLWL.S. Wyrwicz
- P. YañezPYP. Yañez
- Y. BaiYBY. Bai
- M.-H. RyuMRM.-H. Ryu
- J. LeeJLJ. Lee
- F. RiveraFRF. Rivera
- G. Vasconcelos AlvesGAG. Vasconcelos Alves
- M. GarridoMGM. Garrido
- K.-K. ShiuKSK.-K. Shiu
- M. González FernándezMFM. González Fernández
- J. LiJLJ. Li
Open Access
Abstract
No abstract availableFunding Information
- Merck
This publication has 14 references indexed in Scilit:
- 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinomaAnnals of Oncology, 2024
- Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialGastric Cancer, 2024
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023Cancer Communications, 2023
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2023
- Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialThe Lancet, 2023
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2022
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerNature, 2021
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)Annals of Oncology, 2018